Accumulated reports have confirmed that IL-23 participates in the development of some autoimmune inflammatory diseases, including psoriasis, arthritis, and inflammatory bowel disease, thus serving as a critical therapeutic target for the improvement of inflammatory diseases [8, -10]. This evidence concerns the gene IL37 and psoriasis.